Erratum for Yahav et al., "New β-Lactam-β-Lactamase Inhibitor Combinations"
- PMID: 33504504
- PMCID: PMC7849239
- DOI: 10.1128/CMR.00021-21
Erratum for Yahav et al., "New β-Lactam-β-Lactamase Inhibitor Combinations"
Erratum for
-
New β-Lactam-β-Lactamase Inhibitor Combinations.Clin Microbiol Rev. 2020 Nov 11;34(1):e00115-20. doi: 10.1128/CMR.00115-20. Print 2020 Dec 16. Clin Microbiol Rev. 2020. PMID: 33177185 Free PMC article. Review.
Similar articles
-
Novel β-Lactam/β-Lactamase inhibitor combinations vs alternative antibiotics in the treatment of complicated urinary tract infections: A meta-analysis of randomized controlled trials.Medicine (Baltimore). 2020 May;99(19):e19960. doi: 10.1097/MD.0000000000019960. Medicine (Baltimore). 2020. PMID: 32384444 Free PMC article.
-
Activity of beta-lactamase inhibitor combinations on Escherichia coli isolates exhibiting various patterns of resistance to beta-lactam agents.Eur J Clin Microbiol Infect Dis. 1995 Nov;14(11):972-8. doi: 10.1007/BF01691379. Eur J Clin Microbiol Infect Dis. 1995. PMID: 8654448
-
Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.Diagn Microbiol Infect Dis. 1992 May-Jun;15(4):321-30. doi: 10.1016/0732-8893(92)90018-o. Diagn Microbiol Infect Dis. 1992. PMID: 1611847
-
β-Lactamase inhibitors: what you really need to know.Curr Opin Pharmacol. 2017 Oct;36:86-93. doi: 10.1016/j.coph.2017.09.001. Epub 2017 Oct 27. Curr Opin Pharmacol. 2017. PMID: 29096172 Review.
-
A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations.Ann Pharmacother. 1996 Oct;30(10):1130-40. doi: 10.1177/106002809603001013. Ann Pharmacother. 1996. PMID: 8893121 Review.
Cited by
-
Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion.Antibiotics (Basel). 2022 Sep 17;11(9):1263. doi: 10.3390/antibiotics11091263. Antibiotics (Basel). 2022. PMID: 36140042 Free PMC article. Review.
-
In Vitro Activity of New β-Lactamase Inhibitor Combinations against blaNDM, blaKPC, and ESBL-Producing Enterobacteriales Uropathogens.Antibiotics (Basel). 2023 Sep 25;12(10):1481. doi: 10.3390/antibiotics12101481. Antibiotics (Basel). 2023. PMID: 37887182 Free PMC article.
-
Carbapenem-resistant Enterobacterales bloodstream infections related to death in two Brazilian tertiary hospitals.BMC Infect Dis. 2025 May 21;25(1):725. doi: 10.1186/s12879-025-11115-x. BMC Infect Dis. 2025. PMID: 40399841 Free PMC article.
-
In Vitro Activity of Ceftibuten/VNRX-5236 against Urinary Tract Infection Isolates of Antimicrobial-Resistant Enterobacterales.Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0130421. doi: 10.1128/AAC.01304-21. Epub 2021 Oct 18. Antimicrob Agents Chemother. 2022. PMID: 34662183 Free PMC article.
-
The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms.J Clin Microbiol. 2022 Jul 20;60(7):e0080721. doi: 10.1128/jcm.00807-21. Epub 2022 Apr 7. J Clin Microbiol. 2022. PMID: 35387484 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources